Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Keywords: Abstract
- LDLcholesterol
Treatmentprotocol fordyslipidaemia
- Risk calculationmodels
- Cardiovascular risk Introduction. Cardiovascular disease causes more than 4 million deaths annually in Europe and are the
categories primary cause of global morbidity and mortality in both men and women. High levels of LDL (CLDL)
cholesterol constitute a major cardiovascular risk (CVR) factor; one of the fundamental objectives of
- Statins cardiovascularprevention is to lower these levels.
Treatment. In recent years, in an attempt at simplification, there has been a paradigm shift in the
treatment of dyslipidaemia. LDL cholesterol remains the main therapeutic target; however it is no longer
used as an explicit objective and has been changed for an individualised strategy based on absolute CVR
stratification. Therefore, there are three stages to the therapeutic approach: establishing the patient’s
CVR,setting anindividual c-LDL objective, andputtingtogether a therapeutic plan.
TABLA1
RecomendacionessobrelosobjetivosterapéuticosaalcanzardecolesterolLDL
Fig.1. EstrategiasdeintervenciónenfuncióndelriesgocardiovascularyelcolesterolLDL(c-LDL).
Fibra
Actividad física La evidencia disponible demuestra que la fibra soluble en
agua (presente en el salvado de avena y el betaglucano de la
Se recomienda ejercicio físico adaptado a la edad y la situa-
cebada) reduce tanto la concentración de CT como de c-LDL.
ción clínica del paciente, al menos 30 minutos al día de in-
Los alimentos ricos en estas fibras se toleran bien y están
tensidad moderada.
recomendados para recudir el c-LDL en una dosis de al me-
nos 3 g/día.
✔ Metaanálisis ✔ de
dyslipemia and prevention of cardiovascular disease. Endocr Pract.
Artículo derevisión
✔ ✔ ✔
2017;23Suppl2:1-87.
Ensayo clínico controlado Guía práctica clínica 6. Expert Panel on Detection, Evaluation, and Treatment of High Blood
✔ Epidemiología
Cholesterol in Adults: Executive Summary of the Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on De-
tection, Evaluation, and Treatment of High Blood Cholesterol in Adults
✔
(Adult Treatment Panel III). JAMA. 2001;285:2486-97.
✔
7. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blac-
1. Townsend N , Nichols M, Scarborough P, Rayner M. Cardiovascular di- kwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and
sease in Europe—epidemiological update 2015. Eur Heart J. safety of more intensive lowering of LD L cholesterol: a meta-analysis of
✔
2015;36:2696-705. data from 170,000 participants in 26 randomised trials. Lancet.
✔
2. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, 2010;376:1670-81.
et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: 8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux
✔
the SCORE project. EurHeart J. 2003;24:987-1003. P, et al. Ezetimibe added to statin therapy after acute coronary syndro-
✔
3. Catapano AL, Graham I, De Backer G, W iklund O, Chapman MJ, Drexel mes. N Engl J Med. 2015;372:2387-97.
H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidae- 9. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J,
✔
mias. Eur Heart J. 2016;37(39): 2999-3058. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovas-
✔
4. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz C N , Blum CB, cular events. N Engl J Med. 2015; 727:1500-9.
Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood 10. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Mur-
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a re- phy SA, et al. Evolocumab and Clinical Outcomes in Patients with Car-
port of the American College of Cardiology/American Heart Association diovascular Disease. N Engl J Med. 2017;376(18):1713-22.